1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
• Market Definition and Scope
• Executive Summary
• Market Snippet, By Product Type
• Market Snippet, By Drug Class
• Market Snippet, By Disease Indication
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Drivers
• Restraints
• Market Opportunities
• Impact Analysis
• Recent Product Approval/Launch
• Merger-Acquisition Scenario
• Regulatory Scenario
• Reimbursement Scenario
• Pest Analysis
• Market Challenges
• Top 10 Non-oncology Biologics Brand Share
• Major Biopharmaceuticals Administration Method
• Analysis Of Mode Of Administration
• Epidemiology
• Pest Analysis
• Porter’s Five Forces Analysis

4. U.S. Non-oncology Biopharmaceuticals Market, By Product Type, 2026-2033(USD Bn)

• Introduction
• Market Share Analysis, 2025, 2028, and 2033 (%)
• Y-o-Y Growth Analysis, 2021 - 2033
• Segment Trends
• Biologics
• Market Share Analysis, 2025, 2028, and 2033 (%)
• Y-o-Y Growth Analysis, 2021 - 2033
• Segment Trends
• Biosimilars
• Market Share Analysis, 2025, 2028, and 2033 (%)
• Y-o-Y Growth Analysis, 2021 - 2033
• Segment Trends

5. U.S. Non-oncology Biopharmaceuticals Market, By Drug Class, 2026-2033(USD Bn)

• Introduction
• Market Share Analysis, 2025, 2028, and 2033 (%)
• Y-o-Y Growth Analysis, 2021 - 2033
• Segment Trends
• Blood Factors
• Market Share Analysis, 2025, 2028, and 2033 (%)
• Y-o-Y Growth Analysis, 2021 - 2033
• Segment Trends
• Botulinum Toxin
• Market Share Analysis, 2025, 2028, and 2033 (%)
• Y-o-Y Growth Analysis, 2021 - 2033
• Segment Trends
• Colony-stimulating Factor
• Market Share Analysis, 2025, 2028, and 2033 (%)
• Y-o-Y Growth Analysis, 2021 - 2033
• Segment Trends
• Enzyme Replacement Therapy
• Market Share Analysis, 2025, 2028, and 2033 (%)
• Y-o-Y Growth Analysis, 2021 - 2033
• Segment Trends
• Erythropoietin
• Market Share Analysis, 2025, 2028, and 2033 (%)
• Y-o-Y Growth Analysis, 2021 - 2033
• Segment Trends
• Fusion Protein
• Market Share Analysis, 2025, 2028, and 2033 (%)
• Y-o-Y Growth Analysis, 2021 - 2033
• Segment Trends
• Human Growth Hormone
• Market Share Analysis, 2025, 2028, and 2033 (%)
• Y-o-Y Growth Analysis, 2021 - 2033
• Segment Trends
• Interferon
• Market Share Analysis, 2025, 2028, and 2033 (%)
• Y-o-Y Growth Analysis, 2021 - 2033
• Segment Trends
• Monoclonal Antibody
• Market Share Analysis, 2025, 2028, and 2033 (%)
• Y-o-Y Growth Analysis, 2021 - 2033
• Segment Trends
• Recombinant Human Insulin
• Market Share Analysis, 2025, 2028, and 2033 (%)
• Y-o-Y Growth Analysis, 2021 - 2033
• Segment Trends
• Vaccines
• Market Share Analysis, 2025, 2028, and 2033 (%)
• Y-o-Y Growth Analysis, 2021 - 2033
• Segment Trends
• Others
• Market Share Analysis, 2025, 2028, and 2033 (%)
• Y-o-Y Growth Analysis, 2021 - 2033
• Segment Trends

6. U.S. Non-oncology Biopharmaceuticals Market, By Disease Indication, 2026-2033 (USD Bn)

• Introduction
• Market Share Analysis, 2025, 2028, and 2033 (%)
• Y-o-Y Growth Analysis, 2021 - 2033
• Segment Trends
• Age-related Macular Degeneration
• Market Share Analysis, 2025, 2028, and 2033 (%)
• Y-o-Y Growth Analysis, 2021 - 2033
• Segment Trends
• Anemia
• Market Share Analysis, 2025, 2028, and 2033 (%)
• Y-o-Y Growth Analysis, 2021 - 2033
• Segment Trends
• Ankylosing Spondylitis
• Market Share Analysis, 2025, 2028, and 2033 (%)
• Y-o-Y Growth Analysis, 2021 - 2033
• Segment Trends
• Crohn’s Disease
• Market Share Analysis, 2025, 2028, and 2033 (%)
• Y-o-Y Growth Analysis, 2021 - 2033
• Segment Trends
• Cystic Fibrosis
• Market Share Analysis, 2025, 2028, and 2033 (%)
• Y-o-Y Growth Analysis, 2021 - 2033
• Segment Trends
• Diabetes
• Market Share Analysis, 2025, 2028, and 2033 (%)
• Y-o-Y Growth Analysis, 2021 - 2033
• Segment Trends
• Hemophilia
• Market Share Analysis, 2025, 2028, and 2033 (%)
• Y-o-Y Growth Analysis, 2021 - 2033
• Segment Trends
• Hepatitis B
• Market Share Analysis, 2025, 2028, and 2033 (%)
• Y-o-Y Growth Analysis, 2021 - 2033
• Segment Trends
• Multiple Sclerosis
• Market Share Analysis, 2025, 2028, and 2033 (%)
• Y-o-Y Growth Analysis, 2021 - 2033
• Segment Trends
• Osteoporosis
• Market Share Analysis, 2025, 2028, and 2033 (%)
• Y-o-Y Growth Analysis, 2021 - 2033
• Segment Trends
• Psoriasis
• Market Share Analysis, 2025, 2028, and 2033 (%)
• Y-o-Y Growth Analysis, 2021 - 2033
• Segment Trends
• Psoriatic Arthritis
• Market Share Analysis, 2025, 2028, and 2033 (%)
• Y-o-Y Growth Analysis, 2021 - 2033
• Segment Trends
• Rheumatoid Arthritis
• Market Share Analysis, 2025, 2028, and 2033 (%)
• Y-o-Y Growth Analysis, 2021 - 2033
• Segment Trends
• Ulcerative Colitis
• Market Share Analysis, 2025, 2028, and 2033 (%)
• Y-o-Y Growth Analysis, 2021 - 2033
• Segment Trends
• Others
• Market Share Analysis, 2025, 2028, and 2033 (%)
• Y-o-Y Growth Analysis, 2021 - 2033
• Segment Trends

7. Competitive Landscape

• Heat Map Analysis
• Company Profiles
• Sanofi S.A.
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
• Pfizer, Inc.
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
• Johnson & Johnson
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
• Novartis International AG
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
• Amgen, Inc.
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
• Eli Lilly and Company
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
• AbbVie Inc.
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
• Bristol - Myers Squibb Company
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
• F. Hoffmann-La Roche AG
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
• Novo Nordisk A/S
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
• GlaxoSmithKline plc.
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
• UCB Pharma
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
• Teva Pharmaceutical Industries Ltd.
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
• Takeda Pharmaceutical Company Ltd
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
• AstraZeneca Plc
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
• Mylan N.V.
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
• LEO Pharma A/S
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
• Boehringer Ingelheim GmbH
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
• Alexion Pharmaceuticals Inc.
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
• Merck & Co., Inc.
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
• Elusys Therapeutics, Inc.
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
• Swedish Orphan Biovitrum AB
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
• Samsung Bioepis NL B.V.
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
• Biogen Inc.
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
• Theratechnologies Inc.
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies

8. Section

• References
• Research Methodology
• About us and Sales Contact